161 related articles for article (PubMed ID: 24826387)
1. [IV. Targeted therapies for epithelial ovarian cancer].
Mabuchi S; Sasano T; Kawano M; Kimura T
Gan To Kagaku Ryoho; 2014 Feb; 41(2):193-8. PubMed ID: 24826387
[No Abstract] [Full Text] [Related]
2. [Maintenance therapy in patients with advanced epithelial ovarian cancer-impact of anti-angiogenic molecular targeted agents in progress].
Takeuchi S; Sugiyama T
Gan To Kagaku Ryoho; 2014 Aug; 41(8):937-43. PubMed ID: 25132025
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
4. Epithelial ovarian cancer: focus on targeted therapy.
Pliarchopoulou K; Pectasides D
Crit Rev Oncol Hematol; 2011 Jul; 79(1):17-23. PubMed ID: 20674385
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
6. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
[TBL] [Abstract][Full Text] [Related]
7. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
Jackson AL; Eisenhauer EL; Herzog TJ
Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
[TBL] [Abstract][Full Text] [Related]
9. From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer.
Gómez-Raposo C; Mendiola M; Barriuso J; Hardisson D; Redondo A
Expert Opin Investig Drugs; 2011 May; 20(5):591-4. PubMed ID: 21452927
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
11. [Molecular targeted therapies for epithelial ovarian cancer].
Itamochi H; Kigawa J
Nihon Rinsho; 2012 Jun; 70 Suppl 4():622-7. PubMed ID: 23156321
[No Abstract] [Full Text] [Related]
12. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
13. Targeting the tumour microenvironment in ovarian cancer.
Hansen JM; Coleman RL; Sood AK
Eur J Cancer; 2016 Mar; 56():131-143. PubMed ID: 26849037
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
Monk BJ; Dalton H; Farley JH; Chase DM; Benjamin I
Crit Rev Oncol Hematol; 2013 May; 86(2):161-75. PubMed ID: 23137764
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapies for Ovarian Cancer.
Grunewald T; Ledermann JA
Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():139-152. PubMed ID: 28111228
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
17. [III. Chemotherapeutic strategy for histological subtypes of epithelial ovarian cancer].
Kojima A; Sugiyama T
Gan To Kagaku Ryoho; 2014 Feb; 41(2):188-92. PubMed ID: 24826386
[No Abstract] [Full Text] [Related]
18. Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Asmane I; Kurtz JE; Bajard A; Guastalla JP; Meeus P; Tredan O; Labidi Galy I; Moullet I; Ardisson P; Vincent L; Coeffic D; Dufresne A; Bergerat JP; Ray-Coquard I
Bull Cancer; 2011 Oct; 98(9):80-9. PubMed ID: 21926034
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?
Kaye SB
J Clin Oncol; 2007 Nov; 25(33):5150-2. PubMed ID: 18024860
[No Abstract] [Full Text] [Related]
[Next] [New Search]
